BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22160485)

  • 1. Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review.
    Henry DH; Langer CJ; McKenzie RS; Piech CT; Senbetta M; Schulman KL; Stepanski EJ
    Support Care Cancer; 2012 Sep; 20(9):2089-96. PubMed ID: 22160485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.
    Arneson TJ; Li S; Gilbertson DT; Bridges KR; Acquavella JF; Collins AJ
    Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):857-64. PubMed ID: 22450901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia.
    Yu JM; Shord SS; Cuellar S
    J Oncol Pharm Pract; 2011 Dec; 17(4):360-5. PubMed ID: 20826550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Erythropoiesis-stimulating agent use and blood transfusions for chemotherapy-induced anemia throughout FDA's risk evaluation and mitigation strategy lifecycle.
    Vega A; Zhang R; Wong HL; Wernecke M; Alexander M; Feng Y; Lo AC; Lufkin B; Ryan Q; Izem R; MaCurdy TE; Kelman JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2021 May; 30(5):626-635. PubMed ID: 33534188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Questionnaire-based survey on chemotherapy-induced anemia.
    Tanaka A; Yoshino I; Makino S; Katsumata N; Takahashi K; Kuwano H; Maehara Y; Nishiyama M
    Int J Clin Oncol; 2014; 19(3):411-20. PubMed ID: 24610155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
    Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
    Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of the Risk Evaluation Mitigation Strategy for Erythropoiesis-Stimulating Agents on Their Use and the Incidence of Stroke in Medicare Subjects with Chemotherapy-Induced Anemia with Lung and/or Breast Cancers.
    Hollingsworth K; Romney MC; Crawford A; McAna J
    Popul Health Manag; 2016 Feb; 19(1):63-9. PubMed ID: 26102512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study.
    Aerts JG; Swieboda-Sadlej A; Karanikiotis C; Labourey JL; Galid A; Wheeler T; Pujol B; Van Belle S
    Curr Med Res Opin; 2012 Jul; 28(7):1089-99. PubMed ID: 22642866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Questionnaire-based survey on chemotherapy-induced anemia].
    Tanaka A
    Gan To Kagaku Ryoho; 2014 Apr; 41(4):421-5. PubMed ID: 24743357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
    Canon JL; Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Legg J; Pujol B; Bridges K
    Med Oncol; 2012 Sep; 29(3):2291-9. PubMed ID: 22081263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in anemia treatment among patients with five non-myeloid malignancies treated with chemotherapy in a large integrated health care delivery system in California, 2000-2013.
    Xu L; Xu H; Cannavale K; Sattayapiwat O; Rodriguez R; Page JH; Chao C
    Support Care Cancer; 2016 Jul; 24(7):2989-98. PubMed ID: 26872791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions.
    Hess G; Nordyke RJ; Hill J; Hulnick S
    Am J Hematol; 2010 Nov; 85(11):838-43. PubMed ID: 20976794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in Use of Next-Generation Sequencing in Patients With Solid Tumors by Race and Ethnicity After Implementation of the Medicare National Coverage Determination.
    Sheinson DM; Wong WB; Meyer CS; Stergiopoulos S; Lofgren KT; Flores C; Adams DV; Fleury ME
    JAMA Netw Open; 2021 Dec; 4(12):e2138219. PubMed ID: 34882180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk evaluation mitigation strategy: impact of application of the Food and Drug Adminstration's strategy on use of erythropoiesis-stimulating agents and transfusion in patients with chemotherapy-induced anaemia.
    Hollingsworth K; Romney MC; Crawford A; McAna J
    J Clin Pharm Ther; 2015 Jun; 40(3):299-303. PubMed ID: 25893427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chinese physician perception on the treatment of chemotherapy-induced anemia: online cross-section survey study.
    Zhang J; Du Y; Meng Y; Liu X; Mu Y
    Chin Clin Oncol; 2024 Feb; 13(1):5. PubMed ID: 38453656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
    Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.
    Hendrick F; Davidoff AJ; Zeidan AM; Gore SD; Baer MR
    Medicare Medicaid Res Rev; 2014; 4(4):. PubMed ID: 25485173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Darbepoetin Alfa for Chemotherapy-induced Anemia When Initiated at Hemoglobin ≤10 g/dL.
    Pirker R; Hedenus M; Vansteenkiste J; Hernandez E; Belton L; Terwey JH
    Clin Ther; 2016 Jan; 38(1):122-135.e6. PubMed ID: 26730453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.
    Vekeman F; Bookhart BK; White J; McKenzie RS; Duh MS; Piech CT; Lefebvre P
    Transfusion; 2009 May; 49(5):895-902. PubMed ID: 19175548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.